HAS-BLED Calculator – Bleeding Risk for Anticoagulation
Score bleeding risk in anticoagulated patients using the validated 8-criteria HAS-BLED tool to guide safer anticoagulation therapy decisions.
Answer Yes or No for each clinical criterion. Each Yes adds 1 point. Higher scores indicate increased bleeding risk when prescribing anticoagulants such as warfarin or DOACs.
HAS-BLED Calculator – Bleeding Risk for Anticoagulation
Score bleeding risk in anticoagulated patients using the validated 8-criteria HAS-BLED tool to guide safer anticoagulation therapy decisions.
HAS-BLED calculator examples
About the HAS-BLED calculator
The HAS-BLED score is a validated clinical prediction rule used to estimate the risk of major bleeding in patients with atrial fibrillation (AF) who are being considered for anticoagulation therapy. It was first published by Pister et al. in the journal Chest in 2010, derived from the Euro Heart Survey on AF cohort, and has since been validated in multiple independent datasets across different healthcare systems.
The acronym HAS-BLED stands for Hypertension, Abnormal liver or renal function, Stroke history, Bleeding history or predisposition, Labile INR, Elderly (age >65), and Drugs or alcohol. Each of the eight components scores 1 point when present, giving a theoretical maximum of 8 (though Drugs and Alcohol can each independently score 1 point for a combined maximum of 9 in the extended version). The simplified 0–8 version used in this calculator is the most clinically common implementation.
Clinically, a HAS-BLED score of 0 indicates low bleeding risk, 1–2 is moderate, 3 or more is high, and 5 or more represents very high risk. Importantly, the European Society of Cardiology (ESC) guidelines emphasise that a high HAS-BLED score should not automatically lead to withholding anticoagulation — rather, it should prompt clinicians to identify and correct modifiable risk factors. The correctable components include uncontrolled hypertension, labile INR (through medication adjustment or switching to a direct oral anticoagulant), concurrent antiplatelet or NSAID use, and excessive alcohol intake.
The HAS-BLED score is best interpreted in conjunction with the CHA₂DS₂-VASc stroke risk score. For most patients with AF and a CHA₂DS₂-VASc score of 2 or more (men) or 3 or more (women), the stroke prevention benefit of anticoagulation outweighs the bleeding risk even at moderate HAS-BLED scores. The clinical decision becomes more nuanced when both scores are elevated, requiring shared decision-making between the clinician and the patient.
This calculator is intended as a clinical decision support tool, not as a replacement for clinical judgement. All anticoagulation decisions should be made by a qualified healthcare professional who can account for the patient's full clinical picture, comorbidities, patient preferences, and the specific anticoagulant being considered. Direct oral anticoagulants (DOACs) such as apixaban, rivaroxaban, and dabigatran generally carry lower intracranial bleeding rates than warfarin and may be preferred in patients with elevated HAS-BLED scores, particularly those with a history of labile INR.
Key modifiable HAS-BLED risk factors and their management include: treating hypertension to systolic BP <140 mmHg, optimising INR control or switching to a DOAC to improve time in therapeutic range, discontinuing non-essential antiplatelets and NSAIDs, and counselling on alcohol reduction. Addressing even one or two of these factors can meaningfully lower the bleeding risk score and improve the safety profile of long-term anticoagulation.
HAS-BLED calculator examples
Four clinical profiles illustrating how different combinations of risk factors affect the HAS-BLED score and risk classification.
| Clinical Profile | Score / Risk | Key considerations |
|---|---|---|
| Young patient, no risk factors (all No) | 0 / 8 — Low Risk | Anticoagulation is appropriate. Standard monitoring; reassess annually or when new risk factors develop. |
| Elderly with hypertension and renal dysfunction (HTN, Renal, Elderly = Yes) | 3 / 8 — High Risk | High bleeding risk. Control hypertension aggressively and consider DOAC over warfarin to reduce labile INR risk. |
| Multiple risk factors: HTN, Liver, Renal, Stroke, Labile INR, Elderly, Drugs = Yes | 7 / 8 — Very High Risk | Specialist review required. Correct all modifiable factors. Weigh against stroke risk using CHA₂DS₂-VASc score. |
| Patient on antiplatelets, prior bleed, elderly (Bleeding, Elderly, Drugs = Yes) | 3 / 8 — High Risk | Review antiplatelet necessity. If anticoagulation is started, use a DOAC and schedule frequent follow-up. |
How to use the HAS-BLED calculator
- Review the patient's medical records for each of the eight HAS-BLED criteria: hypertension status, liver and renal function, stroke history, prior bleeding events, INR stability, age, and concurrent medications or alcohol use.
- Click Yes for each criterion that is present and No for each that is absent — all eight fields must be answered before the score can be calculated.
- Click Calculate Risk to see the total score out of 8, the risk band (Low, Moderate, High, or Very High), and a clinical guidance statement.
- Identify and document all modifiable risk factors present — these should be addressed before or alongside anticoagulation therapy.
- Compare the HAS-BLED score with the patient's CHA₂DS₂-VASc stroke score to inform the overall anticoagulation risk–benefit decision.
HAS-BLED calculator FAQ
What is the HAS-BLED score used for?
HAS-BLED estimates the risk of major bleeding in patients with atrial fibrillation who are being considered for, or are already on, anticoagulation therapy. It was developed to help clinicians identify patients who need extra monitoring or risk-factor modification rather than to withhold anticoagulation outright. It is recommended in the ESC AF management guidelines.
What score is considered high bleeding risk?
A HAS-BLED score of 3 or more is generally considered high risk and warrants careful review of the anticoagulation decision, correction of modifiable risk factors, and more frequent follow-up. Scores of 5 or more are very high risk and typically require specialist consultation and an explicit shared decision with the patient.
Does a high HAS-BLED score mean I should stop anticoagulation?
Not automatically. ESC guidelines emphasise that a high HAS-BLED score should trigger correction of modifiable risk factors, not simply the withdrawal of anticoagulation. For most patients with AF and high stroke risk (CHA₂DS₂-VASc ≥2 in men, ≥3 in women), the benefit of stroke prevention still outweighs bleeding risk even at moderate HAS-BLED scores.
Which HAS-BLED risk factors can be modified?
The modifiable factors are: uncontrolled hypertension (target <140 mmHg systolic), labile INR (improve by optimising warfarin dosing or switching to a DOAC), concurrent antiplatelet or NSAID use (discontinue if not essential), and excessive alcohol intake (≥8 units/week). Addressing even one of these can reduce the score and meaningfully improve anticoagulation safety.
How does HAS-BLED compare to other bleeding risk scores?
Several other bleeding risk scores exist, including ORBIT, ATRIA, and HEMORR₂HAGES. Head-to-head studies suggest that HAS-BLED and ORBIT perform comparably in most AF populations. HAS-BLED has the advantage of explicitly highlighting modifiable risk factors, which makes it more actionable clinically. ORBIT may be preferred when INR information is not available.
Should I use HAS-BLED for patients on direct oral anticoagulants (DOACs)?
Yes, HAS-BLED was originally validated in warfarin-treated patients but remains applicable as a general bleeding risk framework for DOAC users. The labile INR criterion is not directly applicable to DOACs (which do not require INR monitoring), and some clinicians score it as zero for DOAC patients unless the patient was previously on warfarin with poor INR control. The other seven criteria apply equally to all anticoagulants.